Review of the genetics of thyroid tumours: Diagnostic and prognostic implications

ANZ Journal of Surgery

Volumn 80, Issue 1-2, 2010, Pages 33-40

  Gilfillan, Christopher P ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Biopsy; Cancer; Genetic mutation; Thyroid

Indexed keywords

DNA;

DIFFERENTIAL DIAGNOSIS; FAMILIAL CANCER; GENETICS; HUMAN; MUTATION; NEEDLE BIOPSY; PAPILLARY CARCINOMA; PATHOLOGY; PROTO ONCOGENE; REVIEW; THYROID NODULE; THYROID TUMOR; FINE NEEDLE ASPIRATION BIOPSY;

BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; DIAGNOSIS, DIFFERENTIAL; DNA, NEOPLASM; HUMANS; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; PROTO-ONCOGENES; THYROID NEOPLASMS; THYROID NODULE;

EID: 76349120585     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2009.05173.x     Document Type: Review

References (61)

1. Mazzaferri EL. Management of a solitary thyroid nodule. N. Engl. J. Med. 1993 328 : 553 559.
2. Bonora E et al. Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas. Br. J. Cancer 2006 95 : 1529 1536.
3. Canzian F et al. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am. J. Hum. Genet. 1998 63 : 1743 1748.
4. Australian Institute of Health and Welfare. Australian Cancer Statistics. [Cited September 2009.] Available from URL: http://www.aihw.gov.au/cancer/data/ index.cfm
5. Pal T et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J. Clin. Endocrinol. Metab. 2001 86 : 5307 5312.
6. Burgess JR et al. Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. J. Clin. Endocrinol. Metab. 1997 82 : 345 348.
7. Hemminki K, Eng C, Chen B. Familial risks for nonmedullary thyroid cancer. J. Clin. Endocrinol. Metab. 2005 90 : 5747 5753.
8. Malchoff CD, Malchoff DM. Familial nonmedullary thyroid carcinoma. Cancer Control 2006 13 : 106 110.
9. McKay JD et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am. J. Hum. Genet. 2001 69 : 440 446.
10. Milano A et al. New molecular targeted therapies in thyroid cancer. Anticancer Drugs 2006 17 : 869 879.
11. Lee S et al. Papillary thyroid carcinoma associated with familial adenomatous polyposis: molecular analysis of pathogenesis in a family and review of the literature. Endocr. J. 2004 51 : 317 323.
12. Hizawa K et al. Association between thyroid cancer of cribriform variant and familial adenomatous polyposis. J. Clin. Pathol. 1996 49 : 611 613.
13. Curtis L et al. Evidence against involvement of APC mutation in papillary thyroid carcinoma. Eur. J. Cancer 1994 30A : 984 987.
14. Cameselle-Teijeiro J et al. Somatic but not germline mutation of the APC gene in a case of cribriform-morular variant of papillary thyroid carcinoma. Am. J. Clin. Pathol. 2001 115 : 486 493.
15. Cetta F et al. The ret/ptc1 oncogene is activated in familial adenomatous polyposis-associated thyroid papillary carcinomas. J. Clin. Endocrinol. Metab. 1998 83 : 1003 1006.
16. Hemmings CT. Thyroid pathology in four patients with Cowden's disease. Pathology 2003 35 : 311 314.
17. Boikos SA, Stratakis CA. Carney complex: pathology and molecular genetics. Neuroendocrinology 2006 83 : 189 199.
18. Sandrini F et al. Regulatory subunit type I-alpha of protein kinase A (PRKAR1A): a tumor-suppressor gene for sporadic thyroid cancer. Genes Chromosomes Cancer 2002 35 : 182 192.
19. Arturi F et al. Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions. Thyroid 2003 13 : 341 343.
20. Hoffmann S et al. Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells. Endocrine 2006 30 : 129 138.
21. Esapa C et al. G protein and thyrotropin receptor mutations in thyroid neoplasia. J. Clin. Endocrinol. Metab. 1997 82 : 493 496.
22. Grieco M et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990 60 : 557 563.
23. Nikiforov YE. RET/PTC Rearrangement - a link between Hashimoto's thyroiditis and thyroid cancer. or not. J. Clin. Endocrinol. Metab. 2006 91 : 2040 2042.
24. Rhoden KJ et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J. Clin. Endocrinol. Metab. 2006 91 : 2414 2423.
25. DeLellis RA. Pathology and genetics of thyroid carcinoma. J. Surg. Oncol. 2006 94 : 662 669.
26. Jhiang SM et al. Thyroid carcinomas in RET/PTC transgenic mice. Recent Results Cancer Res. 1998 154 : 265 270.
27. Pierotti MA et al. Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas. J. Endocrinol. Invest. 1995 18 : 130 133.
28. Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur. J. Endocrinol. 2006 155 : 645 653.
29. Corvi R et al. Frequent RET rearrangements in thyroid papillary microcarcinoma detected by interphase fluorescence in situ hybridization. Lab. Invest. 2001 81 : 1639 1645.
30. Sugg SL et al. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J. Clin. Endocrinol. Metab. 1998 83 : 4116 4122.
31. Adeniran AJ et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am. J. Surg. Pathol. 2006 30 : 216 222.
32. Davies H et al. Mutations of the BRAF gene in human cancer. Nature 2002 417 : 949 954.
33. Xing M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 2005 12 : 245 262.
34. Trovisco V et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch. 2005 446 : 589 595.
35. Ciampi R et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest. 2005 115 : 94 101.
36. Xing M et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2005 90 : 6373 6379.
37. Nikiforova MN et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 2003 88 : 5399 5404.
38. Knauf JA et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005 65 : 4238 4245.
39. Di Cristofaro J et al. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum. Pathol. 2006 37 : 824 830.
40. Hara H et al. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 1994 116 : 1010 1016.
41. Suarez HG et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990 5 : 565 570.
42. Cheung L et al. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 2003 88 : 354 357.
43. Castro P et al. A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation. Int. J. Surg. Pathol. 2005 13 : 235 238.
44. Martelli ML et al. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J. Clin. Endocrinol. Metab. 2002 87 : 4728 4735.
45. Marques AR et al. Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. Br. J. Cancer 2004 91 : 732 738.
46. Wang Y et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J. Clin. Endocrinol. Metab. 2007 92 : 2387 2390.
47. Hou P et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/akt pathway in thyroid cancer. Clin. Cancer Res. 2007 13 : 1161 1170.
48. Maximo V et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hürthle cell) tumours of the thyroid. Br. J. Cancer 2005 92 : 1892 1898.
49. Maximo V et al. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. Am. J. Pathol. 2002 160 : 1857 1865.
50. Asakawa H, Kobayashi T. Multistep carcinogenesis in anaplastic thyroid carcinoma: a case report. Pathology 2002 34 : 94 7.
51. Moretti F et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1997 14 : 729 740.
52. Garcia-Rostan G et al. β-catenin dysregulation in thyroid neoplasms : down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am. J. Pathol. 2001 158 : 987 996.
53. Xing M et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2004 89 : 2867 2872.
54. Jin L et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn. Mol. Pathol. 2006 15 : 136 143.
55. Chung KW et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin. Endocrinol. (Oxf) 2006 65 : 660 666.
56. Letsas KP, Andrikoula M, Tsatsoulis A. Fine needle aspiration biopsy-RT-PCR molecular analysis of thyroid nodules: a useful preoperative diagnostic tool. Minerva Endocrinol. 2006 31 : 179 182.
57. Salvatore G et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2004 89 : 5175 5180.
58. Cheung CC et al. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J. Clin. Endocrinol. Metab. 2001 86 : 2187 2190.
59. Domingues R et al. Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology 2005 16 : 27 31.
60. Sciacchitano S et al. PCR amplification and analysis of ras oncogenes from thyroid cytologic smears. Diagn. Mol. Pathol. 1994 3 : 114 121.
61. Bartolazzi A et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 2008 9 : 543 549.